Cells and animals deficient in protein kinase c epsilon
作者： Robert O. Messing , Clyde W. Hodge
DOI:
关键词:
摘要: The present invention is directed to the production of PKC isozyme epsilon (PKCepsilon)-deficient cells and non-human animals. further identification PKCepsilon as a target for drugs that reduce anxiety. According invention, PKCepsilon-inhibiting compounds act in synergy with acting at GABAalpha receptor. also use modulators modulate alcohol consumption, self-administration other abuse, effects consumptions well inhibitors PKCepsilon, either alone or conjunction allosteric agonists receptors, treat conditions, such addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures, epilepsy, are amenable treatment by receptors. Additional aspects diagnostic methods identifying individuals risk becoming alcoholics abusers kits performing methods.
lens.org 参考文章(14)
R. Roivainen, B. Hundle, R. O. Messing, Protein kinase C and adaptation to ethanol. EXS. ,vol. 71, pp. 29- 38 ,(1994) , 10.1007/978-3-0348-7330-7_4
Jr. G. Erik Jagdmann, Vicinal-substituted carbocyclic compounds as therapeutic agents ,(1994)
Eugene W. Napolitano, Lawrence M. Kauvar, Anna Voronova, Dorit Ron, Nicki J. Vasquez, Daria Mochly-Rosen, Methods to identify modulators of cell signaling ,(1996)
Lubing Zhou, Per A. Peterson, Wai-Ping Leung, Lars Karlsson, H2-m modified transgenic animals ,(1997)
Robert M. Bell, Jeffrey B. Nichols, Robert J. Fogelsong, N-aminoalkyl amide inhibitors of protein kinase c ,(1991)
Kirk R. Thomas, Mario R. Capecchi, Positive-negative selection methods and vectors ,(1993)
Mary George Johnson, Jack B. Jiang, Novel furo-coumarinsulfonamides as protein kinase c inhibitors ,(1992)
Brian Thomas O'neill, Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy ,(1997)
Juliette B.J. Decock, Judith Gillespie-Brown, Peter J. Parker, Peter H. Sugden, Stephen J. Fuller, Classical, novel and atypical isoforms of PKC stimulate ANF‐ and TRE/AP‐1‐regulated‐promoter activity in ventricular cardiomyocytes FEBS Letters. ,vol. 356, pp. 275- 278 ,(1994) , 10.1016/0014-5793(94)01283-0